About Saol Therapeutics
Committed to a brighter future
Saol Therapeutics was founded in 2015 by a leadership group who firmly believes that better is always achievable. In only five years, the company quickly grew to a robust commercial and clinical development organization, building to nearly 100 employees with operations located around the world.
In the years that followed Saol turned around and marketed five mature commercial products, received multiple regulatory approvals , and advanced a pipeline of development products. Saol recently divested all commercialized assets to focus on the true passion of the organization - developing new therapies that advance current standard of care treatments for the benefit of patients and the clinicians that treat them.
Saol’s past success has now positioned the company to focus solely on development. The company currently has three late-stage clinical trials underway within its rapidly growing and fully-funded pipeline – with each program having multiple near-term catalysts to further drive the organizations goals. From a novel agent with multiple potential indications in pain and CNS conditions in two Phase 2 trials, to the conclusion of a Phase 3 trial in an ultra-orphan patient population with no current treatment available today – Saol’s pipeline holds great promise for the future benefit of patients around the world.
Behind Saol is a committed investor base and a highly focused, passionate team allowing the company to nimbly make strategic decisions. Saol Therapeutics continues to chase the belief that better is always achievable and is racing toward a future of possibilities.
Our core values that we live by
Diversity, Equity & Inclusion
We believe that the foundation of an innovative and collaborative organization is its ability to integrate and be flexible in the utilization of the talents of all its members, leveraging their diverse backgrounds to achieve organizational goals.
Executing our vision with strategic partnerships
We are a privately held, clinical-stage pharmaceutical company concentrated on clinical development in CNS disorders such as pain and spasticity, and orphan diseases. Beyond our rapidly growing pipeline, we are also focused on the acquisition of approved prescription products and clinical development stage compounds with a compelling scientific story. We partner with pharmaceutical and biotechnology companies – regardless of size – and academia who are looking for a decisive partner to create value.
Interested in partnering?